Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: Implication for prognosis
Histopathology, Volume 54, No. 6, Year 2009
Notification
URL copied to clipboard!
Description
Aims: Multidrug resistance is a major impediment in chemotherapeutic treatment of ovarian carcinoma patients. The aim of this study was to investigate the expression of multidrug resistance-associated protein 1 (MRP1) and to assess the possible associations with clinicopathological variables and patient outcome in primary ovarian carcinoma. Methods and results: Tumour specimens from 129 patients were obtained before chemotherapy and analysed by immunohistochemistry on tissue microarrays, and by real-time reverse transcriptase-polymerase chain reaction on RNA extracted from formalin-fixed paraffin-embedded tissue specimens using a new technique. Significantly increased MRP1 protein expression was observed in high-grade tumours (P = 0.005) and advanced International Federation of Gynaecology and Obstetrics stages (P = 0.036). On univariate Kaplan-Meier analysis, patients with higher expression of MRP1 protein had significantly decreased overall survival (P = 0.006). On multivariate Cox regression analysis, MRP1 protein expression retained its significance as an independent negative prognostic marker for overall survival (hazard ratio = 6.52, P = 0.003). Furthermore, MRP1 expression correlated with topoisomerase IIα expression both at mRNA and protein level (P < 0.001 and P = 0.023, respectively). Conclusion: In summary, in patients with primary ovarian cancer, overexpression of MRP1 is an adverse marker for patient outcome and cancer aggressiveness. Our data provide a translational basis for further clinical studies on the predictive value of MRP1 expression for response to chemotherapy. © 2009 Blackwell Publishing Limited.
Authors & Co-Authors
Faggad, Areeg
Germany, Berlin
Charité – Universitätsmedizin Berlin
Darb-Esfahani, Silvia
Germany, Berlin
Charité – Universitätsmedizin Berlin
Wirtz, Ralph Markus
Unknown Affiliation
Sinn, Bruno Valentin
Germany, Berlin
Charité – Universitätsmedizin Berlin
Sehouli, Jalid
Germany, Berlin
Charité – Universitätsmedizin Berlin
Könsgen, Dominique
Germany, Berlin
Charité – Universitätsmedizin Berlin
Lage, Hermann
Germany, Berlin
Charité – Universitätsmedizin Berlin
Noske, Aurelia
Germany, Berlin
Charité – Universitätsmedizin Berlin
Weichert, Wilko
Germany, Berlin
Charité – Universitätsmedizin Berlin
Buckendahl, Ann Christin
Germany, Berlin
Charité – Universitätsmedizin Berlin
Budczies, Jan
Germany, Berlin
Charité – Universitätsmedizin Berlin
Müller, Berit Maria
Germany, Berlin
Charité – Universitätsmedizin Berlin
Elwali, Nasr Eldin
Sudan, Wad Medani
University of Gezira
Dietel, Manfred
Germany, Berlin
Charité – Universitätsmedizin Berlin
Denkert, Carsten
Germany, Berlin
Charité – Universitätsmedizin Berlin
Statistics
Citations: 32
Authors: 15
Affiliations: 2
Identifiers
Doi:
10.1111/j.1365-2559.2009.03297.x
ISSN:
03090167
e-ISSN:
13652559
Research Areas
Cancer
Environmental
Health System And Policy
Sexual And Reproductive Health
Study Approach
Quantitative